Karanjin interferes with ABCB1, ABCC1, and ABCG2

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 17, Issue 1, 2014, Pages 92-105

  Michaelis, Martin ^a   Rothweiler, Florian ^a   Nerreter, Thomas ^a   Sharifi, Mohsen ^b   Ghafourian, Taravat ^b   Cinatl Jr , Jindrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; APIGENIN; BREAST CANCER RESISTANCE PROTEIN; FLAVONOL DERIVATIVE; GENISTEIN; KARANJIN; MITOXANTRONE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; NARINGENIN; UNCLASSIFIED DRUG; VINCRISTINE; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; BENZOPYRAN DERIVATIVE; FLAVANONE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; METABOLISM; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATASES; APIGENIN; ATP-BINDING CASSETTE TRANSPORTERS; BENZOPYRANS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVANONES; GENISTEIN; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEINS;

EID: 84896365872     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3bw2s     Document Type: Article

References (28)

1. Aller S., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., Harrell P., Trinh Y., Zhang Q., Urbatsch I., Chang G. 2009. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding. Science. Vol. 323(5922) 1718-1722.
2. Ambudkar S.V., Kimchi-Sarfaty C, Sauna Z.E., Gottesman M.M. 2003. P-glycoprotein: from genomics to mechanism. Oncogene. 22(47):7468-7485.
3. Andersen O. M., Markham K.R. 2006. Flavonoids, Chemistry, biochemistry and applications. Chapter 9. Flavonoid-Protein Interactions. Taylor and Francis Group, LLC. USA.
4. Barnes K.M., Dickstein B., Cutler G.B., Fojo T., Bates S.E. 1996. Steroid transport, accumulation, and antagonism of P-Glycoprotein in multidrug-resistant cells. Biochemistry. 35, 4820-4827.
5. Bois F., Beney C., Boumendjel A., Mariotte A.M., Conseil G., Di Pietro A. 1998. Halogenated chalcones with high-affinity binding to P-glycoprotein: potential modulators of multidrug resistance. J Med Chem. 41(21):4161-4.
6. Boumendjel A., Bois F., Beney C., Mariotte A.M., Conseil G., Di Pietro A. 2001. B-ring substituted 5,7-dihydroxyflavonols with high-affinity binding to P-glycoprotein responsible for cell multidrug resistance. Bioorg Med Chem Lett. 11(1):75-77.
7. Boumendjel A., Di Pietro A., Dumontet C., Barron D. 2002. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev.22(5), 512-29.
8. Broccatelli F., Carosati E., Neri A., Frosini M, Goracci L, Oprea T.I., Cruciania G. 2011. A Novel Approach for Predicting P-glycoprotein (ABCB1) Inhibition Using Molecular Interaction Fields. J Med Chem. 54(6): 1740-1751.
9. Castro A.F., Altenberg G.A. 1997. Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol. 53(1):89-93.
10. Comte G., Daskiewicz J.B., Bayet C., Conseil G., Viornery-Vanier A., Dumontet C., Di Pietro A., Barron D. 2001. C-Isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance. J Med Chem. 44(5):763-8.
11. Conseil G., Baubichon-Cortay H., Dayan G., Jault J.M., Barron D., Di Pietro A. 1998. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA. 95, 9831-6.
12. de Wet H., McIntosh DB., Conseil G., Baubichon-Cortay H., Krell T., Jault J.M., et al. 2001. Sequence Requirements of the ATP-Binding Site within the C-Terminal Nucleotide-Binding Domain of Mouse P-Glycoprotein: Structure-Activity Relationships for flavonoid binding. Biochemistry. 40, 10382-10391.
13. Ekins S., Kim R.B., Leake B.F., Dantzig A.H., Schuetz E.G., Lan L.B., Yasuda K., Shepard R.L., Winter M.A., Schuetz J.D., Wikel J.H., Wrighton S.A. 2002. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Molecular Pharmacology. 61, 964-973.
14. Gatlik-Landwojtowicz E, Äänismaa P, Seelig A. 2006. Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry. 45:3020-32.
15. Gottesman M.M., Pastan I. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:385-427.
16. Gutmann D, Ward A, Urbatsch I, Chang G, Veen H. 2010. Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. Trends in biochemical sciences. Volume 35 (1), 36-42.
17. Jain S., Sareen V., Narula A. 1993. Oestrogenic and pregnancy interceptomy efficiency of a flavonoid mixture from grangea-maderaspatana poir (Artemisia maderaspatana) in the mouse. Phytother Res. 7. 381-383.
18. Jodoin J., Demeule M., Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta. 1542(1/3):149-159.
19. Manthey J.A. 2000. Biological properties of flavonoids pertaining to inflammation. Microcirculation. 7, S29-S34.
20. Matsson P., Pedersen J.M., Norinder U., Bergström C.A.S., Artursson P. 2009. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP, and MRP2 among registered drugs. Pharmaceutical Research, Vol 26(8) 1816-1831.
21. Mitcher L. A., Tekkepalli H., Waner P.B.B., Kuo S., Kuo S., Shanhel D.M., Stewart G. 1982. Naringenin, apigenin and genistein are weak estrogens, which bind to the estrogen receptor and elicit estrogen-induced response. Antimutatagenic and anticarcinogenic effects. Mutant Res. 267. 229-241.
22. Omote H, Al-Shawi MK. 2006. Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys J. 90:4046-59.
23. Rancon S, Chaboud A, Darbour N, Comte G, Bayet C, Simon PN, Raynaud J, Di Pietro A, Cabalion P, Barron D. 2001. Natural and synthetic benzophenones: interaction with the cytosolic binding domain of P-glycoprotein. Phytochemistry. 57(4):553-7.
24. Singh P., Jain S., Bhala M., Goyal R.B., Jayaprokash D., Lohiya N.K. 1990. Wagonin, 5,7-dihydroxy-8-methoxy-flavone as oestrogenic and anti-implantational agent in the rat. Phytother Res. 4. 86-89.
25. Spencer J. P. E. Flavonoids: modulators of brain function? 2008. British Journal of Nutrition 99, ES60-ES77.
26. Squadrito F., Altavilla D., Squadrito G., Saitta A., Cucinotta D., Minutoli L., Deodato B., Ferlito M., Campo G.m., Bova A., Caputi A.P. 2000. Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction induced by ovariectomy in rats. Cardiovasc Res. 45. 454-462.
27. Wang R.B., Kuo C.L., Lien L.L., Lien E.J. 2003. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. Journal of clinical pharmacy and therapeutics. 28. 203-228.
28. Zhang S., Morris M.E. 2003. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 304(3):1258-67.